1. [Home](https://www.g2.com/)
2. ...
3. [Other Life Sciences Software](https://www.g2.com/categories/other-life-sciences)
4. [DrugCard Literature Screening Discussions](https://www.g2.com/products/drugcard-literature-screening/discuss)

[
 ![DrugCard Literature Screening](https://images.g2crowd.com/uploads/product/image/large_detail/large_detail_87b0f913b941af5182e5de5fddfdbce1/drugcard-literature-screening.png "DrugCard Literature Screening")
](/products/drugcard-literature-screening/reviews)

# DrugCard Literature Screening Discussions

DrugCard is an Estonian technology company specializing in pharmacovigilance automation. The company develops an AI-powered platform for automated medical literature screening, regulatory intelligence, and drug safety monitoring. DrugCard covers 146+ countries and monitors over 2,200 local journals not indexed in global databases such as PubMed, reducing literature screening time by up to 70% compared to manual processes. The platform serves pharmaceutical companies, contract research organizations (CROs), and marketing authorization holders (MAHs). In addition to its software, DrugCard offers managed pharmacovigilance services including local and global literature screening, case processing, signal detection, and regulatory writing. Founded in 2021 and headquartered in Tallinn, Estonia, the company has grown to 30 employees and serves clients across Europe, the Middle East, and Asia.

## Be the first to start the conversation

Get answers from real professionals in the G2 community.